KRAS：终于有药可治了。
KRAS: Druggable at Last.
机构信息
Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, USA.
出版信息
Oncologist. 2023 Apr 6;28(4):283-286. doi: 10.1093/oncolo/oyad014.
Abstract
The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.
摘要
阿达格拉西布获批用于非小细胞肺癌是药物研发的一个里程碑。本文述评重点介绍了促成这一突破的研究历程，这将帮助众多 KRAS 突变型癌症患者活得更长、更好。
Zotero 插件